PharmaEngine and Nanobiotix to terminate Asia-Pacific Exclusive License and Collaboration Agreement for NBTXR3

PharmaEngine, Inc. Announces First Results for PEP503(NBTXR3) in Rectal Cancer Study at ASCO-GI 2021